These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30853081)

  • 1. Corrigendum to "Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy" [Oral Oncol. 89 (2019) 40-47].
    Miao J; Wang L; Zhu M; Xiao W; Wu H; Di M; Huang Y; Huang S; Han F; Deng X; Guo X; Zhao C
    Oral Oncol; 2019 Mar; 90():136. PubMed ID: 30853081
    [No Abstract]   [Full Text] [Related]  

  • 2. Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Miao J; Wang L; Zhu M; Xiao W; Wu H; Di M; Huang Y; Huang S; Han F; Deng X; Guo X; Zhao C
    Oral Oncol; 2019 Mar; 90():126-133. PubMed ID: 30853080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Miao J; Wang L; Zhu M; Xiao W; Wu H; Di M; Huang Y; Huang S; Han F; Deng X; Guo X; Zhao C
    Oral Oncol; 2019 Feb; 89():40-47. PubMed ID: 30732957
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study.
    Xiao WW; Huang SM; Han F; Wu SX; Lu LX; Lin CG; Deng XW; Lu TX; Cui NJ; Zhao C
    Cancer; 2011 May; 117(9):1874-83. PubMed ID: 21509764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma" [Oral Oncol. 73 (2017) 118-123].
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Nov; 74():194. PubMed ID: 29031556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy.
    Huang TL; Chien CY; Tsai WL; Liao KC; Chou SY; Lin HC; Dean Luo S; Lee TF; Lee CH; Fang FM
    Head Neck; 2016 Apr; 38 Suppl 1():E1026-32. PubMed ID: 26041548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
    Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Accelerated fractionated radiotherapy with concurrent chemotherapy in advanced nasopharyngeal carcinoma].
    Wang RS; Liu WQ; Li J; Zhang Y; Qin YT
    Ai Zheng; 2003 Sep; 22(9):982-4. PubMed ID: 12969534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy.
    Xue F; Hu CS; He XY
    Chin J Cancer; 2017 Sep; 36(1):76. PubMed ID: 28931426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison the clinical outcomes with altered versus conventional fractionated radiotherapy plus concurrent chemotherapy for advanced nasopharyngeal carcinoma.
    Lin PJ; Twu CW; Liu YC; Lin TY; Wang WY; Lin JC
    Head Neck; 2018 Jun; 40(6):1156-1163. PubMed ID: 29389048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas.
    Du L; Zhang XX; Feng LC; Qu BL; Chen J; Yang J; Liu HX; Xu SP; Xie CB; Ma L
    BMC Cancer; 2017 Aug; 17(1):582. PubMed ID: 28851315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities.
    Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ
    Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
    Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
    Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
    Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
    Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
    Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?
    Jen YM; Lin YS; Su WF; Hsu WL; Hwang JM; Chao HL; Liu DW; Chen CM; Lin HY; Wu CJ; Chang LP; Shueng PW
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):14-22. PubMed ID: 12182970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.